Key Highlights
- Judo Bio secures $100M in initial financing for kidney-targeted medicines.
- Series A co-led by Atlas Venture, TCG, and Droia Ventures.
- Appointment of Rajiv Patni, M.D., as Chief Executive Officer and Board Director.
- Lead platform STRIKE advances novel megalin-STRIKER siRNA therapeutics.
- Initial focus on silencing SLCs to address systemic diseases.
Source: Business Wire
Notable Quotes
- “The Judo team should be applauded for their achievements to date. In a short period, the company has developed a novel platform, demonstrated potent and selective gene knockdown in specific kidney regions, and constructed a pipeline of compelling programs that we are excited to see advanced towards the clinic.” — Kevin Bitterman, Ph.D., Partner at Atlas Venture
- “With Judo Bio’s discovery of novel ligands that result in oligonucleotide delivery to specific kidney cells, diseases that were intractable to this approach may now be within reach.” — John Maraganore, Ph.D., Founder and former CEO at Alnylam
- “With the Series A funding in hand, Judo can build on its solid foundation and nominate a series of development candidates, with efficient and timely proof-of-concept data readouts.” — Rajiv Patni, M.D., CEO at Judo Bio
SoHC's Take
Judo Bio’s success in securing $100 million in financing highlights the growing confidence in targeted genetic medicines. Their focus on kidney-targeted oligonucleotide therapeutics, especially through the innovative STRIKE platform, opens new doors for addressing renal and systemic diseases previously deemed untreatable. The leadership of seasoned industry veterans like Dr. Rajiv Patni strengthens their position to make significant advances, potentially transforming the landscape of RNA-based therapies.
